The first medicine shown to delay symptomatic type-1 diabetes is entering National Health Service (NHS) use in England and Wales, giving some families something that has been almost impossible to offer until now: time.
The drug, teplizumab, can push back the point when people develop symptoms and need lifelong insulin treatment by nearly three years on average, according to the National Institute for Health and Care Excellence. The catch is simple but serious: doctors have to find the disease before the child or adult feels sick.
What teplizumab changes
Teplizumab is an immunotherapy, a treatment that works by calming part of the immune system. In type-1 diabetes, the immune system mistakenly attacks pancreas cells that make insulin, the hormone that helps move sugar out of the blood.
That makes type-1 diabetes very different from type-2 diabetes, which is often, though not always, linked with body weight and insulin resistance. Once type-1 reaches the symptomatic stage, daily life can mean carb counting at breakfast, insulin doses, blood sugar alarms, and the worry of dangerous lows.
Who can get the drug
The recommendation covers adults and children age 8 and older with stage 2, type-1 diabetes. Stage 2 means a blood test shows the immune attack has already begun and blood sugar is starting to change, but there are still no symptoms.
England has up to 90 days to set up access, while Wales has 60 days from June 23, 2026. Scotland and Northern Ireland make access decisions through separate routes.
The study behind it
The main evidence comes from the TN-10 clinical trial, a Type-1 Diabetes TrialNet study led by Kevan Herold at Yale School of Medicine. It enrolled 76 people at high risk and compared teplizumab with an inactive treatment.
The trial found that people given teplizumab developed symptomatic disease later. In the original report, 43% of treated participants developed type-1 diabetes during the study, compared with 72% in the comparison group, and the regulator now cites an average delay of about 32 months.
What treatment looks like
Teplizumab is not a pill and it is not a cure. It is given through an intravenous drip once a day for 14 days in a row, with each infusion lasting at least 30 minutes.
That schedule can be tough. Daily hospital visits, including weekends, are not easy for parents juggling work, school, travel, and the familiar grind of appointments that already comes with chronic illness.
The public list price is roughly $200,000 per course at early July 2026 exchange rates, though the NHS has negotiated a confidential discount with Sanofi. About 1,100 people could be eligible in the first year, falling to about 820 each year once the early backlog is cleared.
Why early testing matters
Here is where the problem lies. Stage 2, type-1 diabetes usually has no signs, so the drug depends on screening that many health systems still do not routinely provide.
The ELSA study, led by researchers including Parth Narendran at the University of Birmingham, screens children and young people in the UK with a finger-stick blood test. Its first phase found early-stage, type-1 diabetes in 160 of 17,283 screened children, showing how hidden the disease can be before thirst, weight loss, and exhaustion appear.
Italy has moved further by creating a national pediatric screening route for type-1 diabetes and celiac disease, a related autoimmune condition. That matters because many people who develop type-1 diabetes have no close family history, so family-based testing alone will miss a large share of future cases.
Families get time
For families already living with type-1 diabetes, the benefit is not abstract. Theo Sebastian-Jenkins was diagnosed at age 4 after tiredness, constant thirst, and weight loss took his parents to emergency care. His mother, Vicky, described the daily routine as something “you never switch off.”
Dima Boichak’s family learned of his risk through a UK research study after a cousin had already been diagnosed. His mother, Elena, said the treatment’s biggest gift was “time,” the chance for a child to live normally before insulin becomes part of every day.
That is why patient groups describe this as more than another diabetes drug. Karen Addington of Breakthrough T1D said families would want more years without the daily burden, while Elizabeth Robertson of Diabetes UK said early detection will be key to fair access.
What comes next
At the end of the day, teplizumab changes the question from “how do we manage this after symptoms begin?” to “can we spot it early enough to slow it down?” That is a big shift, but it also puts pressure on testing, clinics, staffing, and public awareness.
For now, the drug offers a window, not a cure. Still, for a child who might get three more years before insulin shots, food calculations, and nighttime alarms, that window may feel enormous.
The official recommendation has been published by NICE.
